Brind.

Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.

Steady: 1 in the last 7 days Updated wednesday

The latest in this situation

  1. Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
  2. HUMIRA sales dropped 35%, and AbbVie's stock performance was compared against Merck and Eli Lilly.
  3. Merck's revenue growth trails J&J's, while the FDA approved its LIPFENDRA drug.

How it started

4 reports, 3 independent, last reported Fri 00:00. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.

Who's involved

What this event is mainly about
AbbVieJohnson & JohnsonEli Lilly and CompanyMerck

How it developed

Newest first. Tap a step to see who reported it.
  1. Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Sub-event
  2. HUMIRA sales dropped 35%, and AbbVie's stock performance was compared against Merck and Eli Lilly.1 source
  3. Merck's revenue growth trails J&J's, while the FDA approved its LIPFENDRA drug.1 source
  4. Eli Lilly outperformed Johnson & Johnson stock over the past year.Sub-event
  5. J&J stock outperformed AbbVie; Eli Lilly results surpassed AbbVie fundamentals; Merck stock outperformed AbbVie.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped